Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BLFS BioLife Solutions	$24.34 -3.9%	$22.16	$19.10 ▼ $29.55	$1.21B	1.76	539,985 shs	1.30 million shs
CLPT ClearPoint Neuro	$11.55 -1.1%	$11.42	$9.76 ▼ $19.22	$332.03M	0.85	397,990 shs	377,908 shs
MDXG MiMedx Group	$7.11 -0.6%	$6.57	$5.47 ▼ $10.14	$1.06B	1.79	873,588 shs	310,344 shs
TNDM Tandem Diabetes Care	$10.82 +1.5%	$16.59	$9.98 ▼ $47.60	$720.29M	1.46	2.65 million shs	2.13 million shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BLFS BioLife Solutions	-3.87%	+7.32%	+15.68%	+3.18%	-6.02%
CLPT ClearPoint Neuro	-1.11%	+6.75%	+1.94%	-12.37%	+17.50%
MDXG MiMedx Group	-0.56%	+1.28%	+5.96%	+0.85%	+15.61%
TNDM Tandem Diabetes Care	+1.50%	-3.65%	-31.30%	-53.12%	-74.06%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BLFS BioLife Solutions	3.1951 of 5 stars	3.6	3.0	0.0	3.1	2.5	0.6
CLPT ClearPoint Neuro	1.8903 of 5 stars	3.5	1.0	0.0	2.2	0.8	0.6
MDXG MiMedx Group	3.1977 of 5 stars	3.5	4.0	0.0	3.2	1.7	0.6
TNDM Tandem Diabetes Care	4.5752 of 5 stars	4.1	3.0	4.9	2.7	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BLFS BioLife Solutions	3.13	Buy	$31.29	28.54% Upside
CLPT ClearPoint Neuro	3.00	Buy	$19.67	70.27% Upside
MDXG MiMedx Group	3.00	Buy	$12.00	68.78% Upside
TNDM Tandem Diabetes Care	2.20	Hold	$22.67	109.49% Upside

Current Analyst Ratings Breakdown

Latest CLPT, MDXG, TNDM, and BLFS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/11/2025	BLFS BioLife Solutions	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/11/2025	TNDM Tandem Diabetes Care	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$75.00 ➝ $12.00
8/8/2025	BLFS BioLife Solutions	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $32.00
8/8/2025	TNDM Tandem Diabetes Care	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$53.00 ➝ $51.00
8/7/2025	TNDM Tandem Diabetes Care	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$59.00 ➝ $24.00
8/7/2025	TNDM Tandem Diabetes Care	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Neutral	$30.00 ➝ $14.00
8/7/2025	TNDM Tandem Diabetes Care	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$20.00 ➝ $17.00
8/7/2025	TNDM Tandem Diabetes Care	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$20.00 ➝ $13.00
8/7/2025	TNDM Tandem Diabetes Care	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$45.00 ➝ $25.00
8/1/2025	CLPT ClearPoint Neuro	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$8.00 ➝ $9.00
7/31/2025	MDXG MiMedx Group	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$11.00 ➝ $12.00

(Data available from 8/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BLFS BioLife Solutions	$82.25M	14.17	$0.12 per share	206.67	$7.25 per share	3.36
CLPT ClearPoint Neuro	$31.39M	10.46	N/A	N/A	$0.69 per share	16.74
MDXG MiMedx Group	$348.88M	3.02	$0.33 per share	21.58	$1.46 per share	4.87
TNDM Tandem Diabetes Care	$940.20M	0.78	N/A	N/A	$1.97 per share	5.49

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BLFS BioLife Solutions	-$20.18M	-$0.12	N/A	N/A	N/A	-5.39%	0.16%	0.14%	N/A
CLPT ClearPoint Neuro	-$18.91M	-$0.81	N/A	N/A	N/A	-66.15%	-94.44%	-51.58%	N/A
MDXG MiMedx Group	$42.42M	$0.21	33.86	22.22	N/A	8.84%	23.03%	17.09%	10/29/2025 (Estimated)
TNDM Tandem Diabetes Care	-$96.03M	-$3.09	N/A	N/A	N/A	-20.51%	-65.40%	-13.87%	N/A

Latest CLPT, MDXG, TNDM, and BLFS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	CLPT ClearPoint Neuro	-$0.20	-$0.21	-$0.01	-$0.21	$9.20 million	$9.22 million
8/7/2025	Q2 2025	BLFS BioLife Solutions	-$0.02	-$0.33	-$0.31	-$0.33	$23.71 million	$25.42 million
8/6/2025	Q2 2025	TNDM Tandem Diabetes Care	-$0.40	-$0.48	-$0.08	-$0.78	$238.39 million	$240.68 million
7/30/2025	Q2 2025	MDXG MiMedx Group	$0.06	$0.10	+$0.04	$0.06	$90.79 million	$98.61 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BLFS BioLife Solutions	N/A	N/A	N/A	N/A	N/A
CLPT ClearPoint Neuro	N/A	N/A	N/A	N/A	N/A
MDXG MiMedx Group	N/A	N/A	N/A	N/A	N/A
TNDM Tandem Diabetes Care	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BLFS BioLife Solutions	0.03	4.43	3.45
CLPT ClearPoint Neuro	1.46	7.30	2.57
MDXG MiMedx Group	0.08	4.39	3.90
TNDM Tandem Diabetes Care	2.32	2.44	1.88

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BLFS BioLife Solutions	93.24%
CLPT ClearPoint Neuro	30.08%
MDXG MiMedx Group	79.15%
TNDM Tandem Diabetes Care	N/A

Insider Ownership

Company	Insider Ownership
BLFS BioLife Solutions	2.20%
CLPT ClearPoint Neuro	6.97%
MDXG MiMedx Group	1.70%
TNDM Tandem Diabetes Care	1.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BLFS BioLife Solutions	440	47.90 million	46.85 million	Optionable
CLPT ClearPoint Neuro	110	28.43 million	26.45 million	Optionable
MDXG MiMedx Group	870	147.96 million	145.44 million	Optionable
TNDM Tandem Diabetes Care	2,650	67.57 million	66.29 million	Optionable

CLPT, MDXG, TNDM, and BLFS Headlines

Recent News About These Companies

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Given Consensus Rating of "Hold" by Brokerages

August 15 at 2:38 AM | marketbeat.com

Tandem Diabetes Care, Inc. (TNDM) Investors Who Lost Money - Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

August 14 at 11:24 PM | tmcnet.com

Securities Fraud Investigation Into Tandem Diabetes Care, Inc. ...

August 14 at 4:14 PM | gurufocus.com

Securities Fraud Investigation Into Tandem Diabetes Care, Inc. (TNDM) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm

August 14 at 3:00 PM | businesswire.com

Tandem Diabetes Care, Inc. (TNDM) Investors Who Lost Money -- Contact Law Offices of Howard G. ...

August 14 at 1:21 PM | gurufocus.com

Tandem Diabetes Care, Inc. (TNDM) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

August 14 at 12:42 PM | businesswire.com

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Receives Consensus Rating of "Hold" from Analysts

August 14 at 2:38 AM | americanbankingnews.com

Tandem Diabetes Care (NASDAQ:TNDM) Cut to "Hold" at Lake Street Capital

August 14 at 2:03 AM | americanbankingnews.com

Securities Fraud Investigation Into Tandem Diabetes Care, Inc. (TNDM) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

August 13 at 8:44 PM | businesswire.com

Tandem Diabetes Care (NASDAQ:TNDM) Shares Gap Up Following Insider Buying Activity

August 13 at 10:52 AM | marketbeat.com

5 Insightful Analyst Questions From Tandem Diabetes’s Q2 Earnings Call

August 13 at 7:30 AM | finance.yahoo.com

Tandem Diabetes Care: Strategic Growth Potential and Market Expansion Drive Buy Rating

August 13 at 7:14 AM | tipranks.com

Tandem Diabetes Care Gains FDA Clearance for SteadiSet

August 13 at 2:30 AM | theglobeandmail.com

Tandem Diabetes Care (TNDM) was downgraded to a Hold Rating at Piper Sandler

August 13 at 2:30 AM | theglobeandmail.com

Tandem Diabetes Care (NASDAQ:TNDM) Shares Gap Up After Insider Buying Activity

August 13 at 2:08 AM | americanbankingnews.com

Citigroup Upgrades Tandem Diabetes Care (TNDM)

August 12, 2025 | msn.com

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) CEO Acquires $102,300.00 in Stock

August 12, 2025 | marketbeat.com

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) CFO Acquires $149,410.80 in Stock

August 12, 2025 | marketbeat.com

Tandem Diabetes, iRhythm, agilon health, Fortrea, and 10x Genomics Shares Skyrocket and Plummet, What You Need To Know

August 12, 2025 | msn.com

Tandem Diabetes upgraded at Citi on risk-reward setup

August 12, 2025 | msn.com

Tandem Diabetes Care (NASDAQ:TNDM) Given "Hold" Rating at Lake Street Capital

August 12, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLPT, MDXG, TNDM, and BLFS Company Descriptions

BioLife Solutions NASDAQ:BLFS

$24.34 -0.98 (-3.87%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$24.59 +0.25 (+1.03%)

As of 08/15/2025 06:54 PM Eastern

BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line that comprises of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides cryogenic freezer technology for controlled rate freezing and cryogenic storage of biologic materials; ultra-low temperature mechanical freezers; evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage and transport services. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.

ClearPoint Neuro NASDAQ:CLPT

$11.55 -0.13 (-1.11%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$11.54 -0.02 (-0.13%)

As of 08/15/2025 07:55 PM Eastern

ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain. It has license and collaboration agreement with Clinical Laserthermia Systems AB; license and research agreement with Koninklijke Philips N.V., UCB Biopharma SRL, and University of California and San Francisco; and development and license agreement with NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.

MiMedx Group NASDAQ:MDXG

$7.11 -0.04 (-0.56%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$7.12 +0.00 (+0.07%)

As of 08/15/2025 04:20 PM Eastern

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a barrier membrane allograft used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; and EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications. The company's products have applications in the areas of wound care, burn, surgical sectors of healthcare. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. was founded in 2006 and is headquartered in Marietta, Georgia.

Tandem Diabetes Care NASDAQ:TNDM

$10.82 +0.16 (+1.50%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$10.93 +0.11 (+1.02%)

As of 08/15/2025 07:58 PM Eastern

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time